Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 107

1.

Accelerated BEP for metastatic germ cell tumours: a multicenter phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP).

Grimison PS, Stockler MR, Chatfield M, Thomson DB, Gebski V, Friedlander M, Boland AL, Houghton B, Gurney H, Rosenthal M, Singhal N, Kichenadasse G, Wong SS, Lewis CR, Vasey PA, Toner GC; Australian and New Zealand Urogenital and Prostate Cancer Trials Group.

Ann Oncol. 2014 Jan;25(1):143-8. doi: 10.1093/annonc/mdt369.

PMID:
24356625
[PubMed - indexed for MEDLINE]
2.

Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial.

Grimison PS, Stockler MR, Thomson DB, Olver IN, Harvey VJ, Gebski VJ, Lewis CR, Levi JA, Boyer MJ, Gurney H, Craft P, Boland AL, Simes RJ, Toner GC.

J Natl Cancer Inst. 2010 Aug 18;102(16):1253-62. doi: 10.1093/jnci/djq245. Epub 2010 Jul 14.

PMID:
20631341
[PubMed - indexed for MEDLINE]
Free Article
3.

Accelerated BEP: a phase I trial of dose-dense BEP for intermediate and poor prognosis metastatic germ cell tumour.

Rimmer Y, Chester J, Joffe J, Stark D, Shamash J, Powles T, White J, Wason J, Parashar D, Armstrong G, Mazhar D, Williams MV.

Br J Cancer. 2011 Sep 6;105(6):766-72. doi: 10.1038/bjc.2011.309. Epub 2011 Aug 16.

PMID:
21847130
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Intensive induction chemotherapy with C-BOP/BEP for intermediate- and poor-risk metastatic germ cell tumours (EORTC trial 30948).

Fosså SD, Paluchowska B, Horwich A, Kaiser G, de Mulder PH, Koriakine O, van Oosterom AT, de Prijck L, Collette L, de Wit R; EORTC GU Group.

Br J Cancer. 2005 Nov 28;93(11):1209-14.

PMID:
16251877
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Paclitaxel+BEP (T-BEP) regimen as induction chemotherapy in poor prognosis patients with nonseminomatous germ cell tumors: a phase II study.

Tryakin A, Fedyanin M, Kanagavel D, Fainstein I, Sergeev J, Polockij B, Matveev V, Zakharova T, Garin A, Tjulandin S.

Urology. 2011 Sep;78(3):620-5. doi: 10.1016/j.urology.2011.05.005. Epub 2011 Jul 20.

PMID:
21764427
[PubMed - indexed for MEDLINE]
6.
7.

Randomized phase III study comparing paclitaxel-bleomycin, etoposide, and cisplatin (BEP) to standard BEP in intermediate-prognosis germ-cell cancer: intergroup study EORTC 30983.

de Wit R, Skoneczna I, Daugaard G, De Santis M, Garin A, Aass N, Witjes AJ, Albers P, White JD, Germa-Lluch JR, Marreaud S, Collette L.

J Clin Oncol. 2012 Mar 10;30(8):792-9. doi: 10.1200/JCO.2011.37.0171. Epub 2012 Jan 23.

PMID:
22271474
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial.

Horwich A, Sleijfer DT, Fosså SD, Kaye SB, Oliver RT, Cullen MH, Mead GM, de Wit R, de Mulder PH, Dearnaley DP, Cook PA, Sylvester RJ, Stenning SP.

J Clin Oncol. 1997 May;15(5):1844-52.

PMID:
9164194
[PubMed - indexed for MEDLINE]
9.

Management of intermediate-prognosis germ-cell cancer: results of a phase I/II study of Taxol-BEP.

de Wit R, Louwerens M, de Mulder PH, Verweij J, Rodenhuis S, Schornagel J.

Int J Cancer. 1999 Dec 10;83(6):831-3.

PMID:
10597204
[PubMed - indexed for MEDLINE]
10.
11.

Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP.

Culine S, Kramar A, Théodore C, Geoffrois L, Chevreau C, Biron P, Nguyen BB, Héron JF, Kerbrat P, Caty A, Delva R, Fargeot P, Fizazi K, Bouzy J, Droz JP; Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP.

J Clin Oncol. 2008 Jan 20;26(3):421-7. doi: 10.1200/JCO.2007.13.8461.

PMID:
18202419
[PubMed - indexed for MEDLINE]
12.

Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: a randomised trial. Australian and New Zealand Germ Cell Trial Group.

Toner GC, Stockler MR, Boyer MJ, Jones M, Thomson DB, Harvey VJ, Olver IN, Dhillon H, McMullen A, Gebski VJ, Levi JA, Simes RJ.

Lancet. 2001 Mar 10;357(9258):739-45.

PMID:
11253966
[PubMed - indexed for MEDLINE]
13.

Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy.

Kumano M, Miyake H, Hara I, Muramaki M, Takenaka A, Fujisawa M.

Hinyokika Kiyo. 2007 Dec;53(12):851-6.

PMID:
18203521
[PubMed - indexed for MEDLINE]
Free Article
14.

Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group.

de Wit R, Stoter G, Kaye SB, Sleijfer DT, Jones WG, ten Bokkel Huinink WW, Rea LA, Collette L, Sylvester R.

J Clin Oncol. 1997 May;15(5):1837-43.

PMID:
9164193
[PubMed - indexed for MEDLINE]
15.
16.

Bleomycin, etoposide and cisplatinum (BEP) chemotherapy for metastatic germ cell tumours: treatment outcomes at UKM medical centre, Malaysia.

Azrif M, Leong YK, Aslan NM, Fong KV, Ismail F.

Asian Pac J Cancer Prev. 2012;13(6):2467-71.

PMID:
22938405
[PubMed - indexed for MEDLINE]
Free Article
17.

A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with 'good-risk' metastatic non-seminomatous germ cell tumors.

Bokemeyer C, Köhrmann O, Tischler J, Weissbach L, Räth U, Haupt A, Schöffski P, Harstrick A, Schmoll HJ.

Ann Oncol. 1996 Dec;7(10):1015-21.

PMID:
9037359
[PubMed - indexed for MEDLINE]
Free Article
18.

Paclitaxel, bleomycin, etoposide, and cisplatin (T-BEP) as initial treatment in patients with poor-prognosis germ cell tumors (GCT): a phase II study.

Mardiak J, Sálek T, Sycová-Milá Z, Obertová J, Recková M, Mego M, Hlavatá Z, Brozmanová K, Risnyovzská Z, Svetlovská D, Koza I.

Neoplasma. 2007;54(3):240-5.

PMID:
17447857
[PubMed - indexed for MEDLINE]
19.
20.

Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors.

Motzer RJ, Nichols CJ, Margolin KA, Bacik J, Richardson PG, Vogelzang NJ, Bajorin DF, Lara PN Jr, Einhorn L, Mazumdar M, Bosl GJ.

J Clin Oncol. 2007 Jan 20;25(3):247-56.

PMID:
17235042
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk